1
|
Xing J, Singh S, Zhao Y, Duan Y, Guo H, Hu C, Ma A, George R, Xing JZ, Kalluri A, Macwan I, Patra P, Chen J. Increasing vaccine production using pulsed ultrasound waves. PLoS One 2017; 12:e0187048. [PMID: 29176801 PMCID: PMC5703500 DOI: 10.1371/journal.pone.0187048] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2017] [Accepted: 10/12/2017] [Indexed: 01/14/2023] Open
Abstract
Vaccination is a safe and effective approach to prevent deadly diseases. To increase vaccine production, we propose that a mechanical stimulation can enhance protein production. In order to prove this hypothesis, Sf9 insect cells were used to evaluate the increase in the expression of a fusion protein from hepatitis B virus (HBV S1/S2). We discovered that the ultrasound stimulation at a frequency of 1.5 MHz, intensity of 60 mW/cm2, for a duration of 10 minutes per day increased HBV S1/S2 by 27%. We further derived a model for transport through a cell membrane under the effect of ultrasound waves, tested the key assumptions of the model through a molecular dynamics simulation package, NAMD (Nanoscale Molecular Dynamics program) and utilized CHARMM force field in a steered molecular dynamics environment. The results show that ultrasound waves can increase cell permeability, which, in turn, can enhance nutrient / waste exchange thus leading to enhanced vaccine production. This finding is very meaningful in either shortening vaccine production time, or increasing the yield of proteins for use as vaccines.
Collapse
Affiliation(s)
- Jida Xing
- Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada
| | - Shrishti Singh
- Department of Biomedical Engineering, University of Bridgeport, Bridgeport, Connecticut, United States of America
| | - Yupeng Zhao
- Department of Biomedical Engineering, University of Alberta, Edmonton, Canada
| | - Yan Duan
- Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, Canada
| | - Huining Guo
- Department of Physiatry, University of Alberta, Edmonton, Canada
| | - Chenxia Hu
- School of Chinese Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Allan Ma
- Akshaya Bio Inc., Edmonton, Alberta, Canada
| | | | - James Z. Xing
- Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Canada
| | - Ankarao Kalluri
- Department of Biomedical Engineering, University of Bridgeport, Bridgeport, Connecticut, United States of America
| | - Isaac Macwan
- Department of Biomedical Engineering, University of Bridgeport, Bridgeport, Connecticut, United States of America
| | - Prabir Patra
- Department of Biomedical Engineering, University of Bridgeport, Bridgeport, Connecticut, United States of America
- Department of Mechanical Engineering, University of Bridgeport, Bridgeport, Connecticut, United States of America
| | - Jie Chen
- Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada
- Department of Biomedical Engineering, University of Alberta, Edmonton, Canada
- * E-mail:
| |
Collapse
|
2
|
Abstract
Nowadays, gold is used in (nano-)medicine, usually in the form of nanoparticles, due to the solid proofs given of its therapeutic effects on several diseases. Gold also plays an important role in the vaccine field as an adjuvant and a carrier, reducing toxicity, enhancing immunogenic activity, and providing stability in storage. An even brighter golden future is expected for gold applications in this area.
Collapse
Affiliation(s)
- Sónia Alexandra Correia Carabineiro
- Laboratório de Catálise e Materiais (LCM), Laboratório Associado LSRE-LCM, Faculdade de Engenharia, Universidade do Porto, 4200-465 Porto, Portugal.
| |
Collapse
|
3
|
Semenenko TA, Suslov AP. [IMMUNOPATHOGENESIS OF OCCULT INFECTION CAUSED BY HEPATITIS B VIRUS]. Zh Mikrobiol Epidemiol Immunobiol 2015:105-113. [PMID: 26950999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The concept of occult infection caused by hepatitis B virus (HBV) is determined as the presence of HBV DNA in blood sera or liver with the absence of detectable HBsAg. The actuality of this problem is associated with the fact, that occult hepatitis B (OHB) can be transmitted during hemotransfusions, cause reactivation of chronic hepatitis B in immune compromised individuals, facilitate development of liver cirrhosis and hepatocellular carcinoma. Several different hypotheses of OHB immunopathogenesis have been proposed, including a low number of copies of HBV DNA, altered immune response of the macroorganism, genetic variability of the S gene, integration of viral DNA into host genome, infection of mononuclear cells of peripheral blood, presence of immune complexes that hide HBsAg, and interference by other viruses such as HCV and HIV. Molecular mechanisms of HBV virus in HBsAg-negative individuals are not fully understood, however, viral mutations seem a very significant factor. Approaches of OHB prophylaxis including use of a polyvalent vaccine, that allows vaccination against wild and mutant HBV viruses, are examined.
Collapse
MESH Headings
- Antigen-Antibody Complex/blood
- Antigen-Antibody Complex/chemistry
- Carcinoma, Hepatocellular/etiology
- Carcinoma, Hepatocellular/immunology
- Carcinoma, Hepatocellular/pathology
- Carcinoma, Hepatocellular/prevention & control
- DNA Copy Number Variations
- DNA, Viral/blood
- DNA, Viral/immunology
- Hepatitis B Surface Antigens/immunology
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/biosynthesis
- Hepatitis B Vaccines/immunology
- Hepatitis B virus/genetics
- Hepatitis B virus/immunology
- Hepatitis B, Chronic/complications
- Hepatitis B, Chronic/immunology
- Hepatitis B, Chronic/pathology
- Hepatitis B, Chronic/prevention & control
- Humans
- Immune Evasion
- Liver/immunology
- Liver/virology
- Liver Cirrhosis/etiology
- Liver Cirrhosis/immunology
- Liver Cirrhosis/pathology
- Liver Cirrhosis/prevention & control
- Liver Neoplasms/etiology
- Liver Neoplasms/immunology
- Liver Neoplasms/pathology
- Liver Neoplasms/prevention & control
- Mutation
- Vaccination
Collapse
|
4
|
Yang Z, Li S, Liu H, Zhang M, Ye L, Wu Y, Xu M, Chen Z. [Stable and efficient expression of hepatitis B virus S antigen and preS1 epitope fusion protein (S/preS1) in CHO cells]. Sheng Wu Gong Cheng Xue Bao 2013; 29:1808-1816. [PMID: 24660628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Hepatitis B surface antigen (HBsAg) carrying preS sequences could be an ideal candidate for a new hepatitis B virus (HBV) vaccine with higher efficacy. Here we report the success in achieving efficient and stable expression of hepatitis B virus S antigen and preS1 epitope fusion protein (S/preS1) in CHO cells. The HMRCHEF53u/Neo-S/preS1 expression vector carrying S/preS1 gene was constructed and transfected into CHO-S cells. A stable and high-expression CHO cell line, named 10G6, was selected by ELISA and limiting dilution analysis. Western blotting analysis showed S/preS1 expressed from 10G6 cells possessed both S and preS1 antigenicity. 10G6 cells displayed characters of favorable growth and stable S/preS1 expression in repeated batch cultures as evaluated by viable cell density, viability and S/preS1 concentration. And cultivation of 10G6 cells in fed-batch mode resulted in S/preS1 production at 17-20 mg/L with viable cell density at 7 x 10(6)-10 x 10(6) cells/mL.
Collapse
|
5
|
Hayden CA, Egelkrout EM, Moscoso AM, Enrique C, Keener TK, Jimenez-Flores R, Wong JC, Howard JA. Production of highly concentrated, heat-stable hepatitis B surface antigen in maize. Plant Biotechnol J 2012; 10:979-84. [PMID: 22816734 PMCID: PMC3517206 DOI: 10.1111/j.1467-7652.2012.00727.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Plant-based oral vaccines are a promising emergent technology that could help alleviate disease burden worldwide by providing a low-cost, heat-stable, oral alternative to parenterally administered commercial vaccines. Here, we describe high-level accumulation of the hepatitis B surface antigen (HBsAg) at a mean concentration of 0.51%TSP in maize T1 seeds using an improved version of the globulin1 promoter. This concentration is more than fourfold higher than any previously reported lines. HBsAg expressed in maize seeds was extremely heat stable, tolerating temperatures up to 55 °C for 1 month without degradation. Optimal heat stability was achieved after oil extraction of ground maize material, either by supercritical fluid extraction or hexane treatment. The contributions of this material towards the development of a practical oral vaccine delivery system are discussed.
Collapse
Affiliation(s)
- Celine A. Hayden
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407
| | - Erin M. Egelkrout
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407
| | - Alessa M. Moscoso
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407
| | - Cristina Enrique
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407
| | - Todd K. Keener
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407
| | - Rafael Jimenez-Flores
- Dairy Science Department, California Polytechnic State University, San Luis Obispo, CA 93407
| | - Jeffrey C. Wong
- Horticulture and Crop Science Department, California Polytechnic State University, San Luis Obispo, CA 93407
| | - John A. Howard
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407
| |
Collapse
|
6
|
Rukavtsova EB, Chebotareva EN, Rudenko NV, Buryanov YI. Immunogenicity of biologically safe potato tubers synthesizing hepatitis B surface antigen. Dokl Biol Sci 2011; 437:110-112. [PMID: 21562959 DOI: 10.1134/s001249661102013x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2010] [Indexed: 05/30/2023]
Affiliation(s)
- E B Rukavtsova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino Branch, Pushchino, Moscow oblast, Russia
| | | | | | | |
Collapse
|
7
|
Abstract
Mucosal vaccination is a perspective for the control of infectious diseases, since it is capable of inducing humoral and cell-mediated responses. In addition, the delivery of vaccines to mucosal surfaces makes immunization practice safe and acceptable, and eliminates needle-associated risks. Transgenic plants can be used as bioreactors for the production of mucosally delivered protective antigens. This technology shows great promise to simplify and decrease the cost of vaccine delivery. Herein, we review the development of mucosally administered vaccines expressed in transgenic plants. In particular, we evaluate the advantages and disadvantages of using plants for the production of mucosal vaccines against widespread infectious diseases such as HIV, hepatitis B and TB.
Collapse
Affiliation(s)
- Rurick K Salyaev
- Siberian Institute of Plant Physiology and Biochemistry of The Siberian Branch of the RAS, Irkutsk, Russia.
| | | | | |
Collapse
|
8
|
Ferro W, Geada D, Guevara Y, Padilla S, Conde A, Alvarez T, Medina Y, González T, Wood M, Valdés R. Prolonged stability of the plantibody HB-01 directed against the hepatitis B surface antigen in cryo-preserved tobacco leaves. Biologicals 2010; 38:415-9. [PMID: 20303783 DOI: 10.1016/j.biologicals.2010.02.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2008] [Revised: 02/05/2010] [Accepted: 02/11/2010] [Indexed: 11/16/2022] Open
Abstract
Since 1983, several recombinant antibodies have been expressed in important agronomic plant species. However, to date no evaluation has been published about prolonged antibody stability within plant tissues under cryo-preservation conditions. This current report presents an approach to the KDEL-plantibody HB-01 (PHB-01) stability in frozen tobacco leaves by presenting scientific evidence about the stability of a plantibody to a prolonged low temperature exposure in this biological source. Results clearly show that the PHB-01 amount is maintained during the storage of tobacco leaves at -20 degrees C for 90 days. The PHB-01 recovery was not affected by any irreversible physical and/or chemical change produced in tobacco leaves after this cryo-preservation time. The amount of total soluble proteins in the clarified extract decreased in proportion with the storage time and the PHB-01 molecules isolated from frozen leaf extracts were highly pure, >95%, according to an SDS-PAGE assessment under reducing conditions. Low temperature exposure of tobacco leaves did not reveal visible changes in frozen leaves, which is essential for the further extractability of proteins. The PHB-01 is stable in tobacco leaves at -20 degrees C during 90 days, which offers the possibility to overcome problems associated with detrimental climate conditions and optimize purification capabilities.
Collapse
Affiliation(s)
- Williams Ferro
- Monoclonal Antibody Production Department, Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, Havana 10600, P.O. Box 6162, Cuba
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Chen H, Deng Y, Tan W, Wang W, Yin X, Guan J, Wang W, Ruan L. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice]. Sheng Wu Gong Cheng Xue Bao 2010; 26:74-78. [PMID: 20353095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
We previous reported the development of novel hepatitis B virus(HBV) vaccine containing the surface antigen(S) plus PreS1 fusion derived from Chinese hamster ovary (CHO) cells system. In this study, we analyzed the impact of different adjuvants on immunogenicity of the HBV particle vaccine in Balb/C mice, including alum alone, CpG oligodeoxynucleotides (CpG-ODN) alone and CpG-ODN in combination with alum adjuvant. We first detected the antigen specific humoral response in mice, including total IgG antibody and IgG subtyping. Then, we characterized the specific cell-mediated immune (CMI) response by detection of gamma-interferon secreting splenocytes after stimulating with S or PreS1 peptide pool. Our results showed that: CpG-ODN adjuvanted vaccine could rapidly induce higher level of anti-PreS 1 and anti-S antibodies, and a higher ratio of IgG2a/IgG1 antibody than that of alum adjuvanted vaccine. At the same time, CpG-ODN adjuvanted vaccine induced robust antigen-specific cellular immune responses in mice, which was superior to that of alum adjuvanted vaccine and CpG-ODN in combination with alum adjuvanted vaccine; however, the vaccine candidate with CpG-ODN in combination with alum adjuvant induced highest anti-S antibody and mixed IgG subclasses in mice after twice immunization. There exists dominant HBV CMI epitopes in the N-terminal of S antigen. These results provided important evidence that CpG-ODN adjuvanted HBSS1 particles vaccine may serve as a novel candidate in the development of new preventive and therapeutic agents against hepatitis B infection.
Collapse
Affiliation(s)
- Hong Chen
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Guo Y, Hui CY. [Pilot-scale production and quality control of multiepitope hepatitis B virus DNA vaccine]. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29:118-120. [PMID: 19218129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
OBJECTIVE To establish a method for pilot-scale production and quality control of multiepitope hepatitis B virus (HBV) DNA vaccine (PVAX-HS). METHODS Recombinant DH5alpha/pVAX-HS was obtained by fed-batch fermentation, and the plasmid was extracted by alkaline lysis and concentrated by ultrafiltration. The plasmid DNA was purified by a three-step column chromatography to obtain the DNA vaccine, and quality control tests were performed on the final product. RESULTS The quantity of the fed-batch product reached 50-60 g/L, and the final plasmid output was 1.0 mg per gram of the bacteria. The quality of the DNA vaccine met the requirements for medical use. CONCLUSION A simple and stable procedure was established for pilot-scale production of multiepitope HBV DNA vaccine, which allows potential large-scale production of the DNA vaccine.
Collapse
Affiliation(s)
- Yan Guo
- National Hepatobiliary and Enteric Surgery Research Center of Ministry of Health, Central South University, Changsha, 410078, China.
| | | |
Collapse
|
11
|
Tan CY, Yuan J, Jin O, Jiang LM, Hu B. [Preparation and immunogenicity of a Pichia pastoris-derived hepatitis B vaccine containing preS1, preS2 and S epitopes]. Sheng Wu Gong Cheng Xue Bao 2007; 23:700-3. [PMID: 17822047 DOI: 10.1016/s1872-2075(07)60046-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The preparation process and immunogenicity of a novel hepatitis B vaccine containing preS1, preS2 and S epitopes were investigated in this study. A Pichia pastoris stain GS115-SS1S2 harbouring two chimeric HBsAg gene constructs, SS1 and SS2 was cultivated by high-density fermentation. 300-600 mg/L of the expression level was achieved through 48-72 h methanol induction. SSIS2 antigen was extracted and purified by silica adsorption, HIC and SEC to 99% purity from the harvested cells. 82 mg purified antigen could be achieved from one liter of fermentation culture. The immunogenicity of the purified antigen was evaluated in NIH mice. Three groups of female NIH mice, 14-16 g in weight, were injected once intraperitoneally with 2.5, 0.625, 0.156 microg of each of the two vaccines: SS1S2 or a commercially available S vaccine. Part of the mice were bled in 30 days after injection to compare the ED50 of the two vaccines. For the SSIS2 vaccine, the ED50 is 0.46, 0.29 and 0.84 microg respectively for the preS1, preS2 and S antigens. For the S vaccine, the ED50 is 0.99 microg for the S antigen. Another part of the mice were bleed in 7 or 14 days to detect preS1, preS2 and S antibodies. Higher ratios of mice were seroconverted for preS1 and preS2 antibodies as compared to the S antibody in these two time points. These results suggest that the SS1S2 vaccine may be more immunogenic than the conventional S vaccines.
Collapse
Affiliation(s)
- Chang-Yao Tan
- Laboratory of Biotechnology, Chengdu Institute of Biological Products, Chengdu 610023, China.
| | | | | | | | | |
Collapse
|
12
|
Zhang Y, Song S, Liu C, Wang Y, Xian X, He Y, Wang J, Liu F, Sun S. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. Cell Immunol 2007; 247:18-27. [PMID: 17707782 DOI: 10.1016/j.cellimm.2007.07.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2007] [Revised: 06/29/2007] [Accepted: 07/03/2007] [Indexed: 12/18/2022]
Abstract
The major aim of the project was to develop the virus-like particles (VLPs) displaying single or multi-epitope of hepatocellular carcinomas (HCC) in Escherichia coli and to evaluate the effect on inducing Ag-specific CD8(+) T cell response and antitumor efficacy as candidate vaccines. To this end, hepatitis B virus core (HBc) particles were used as a carrier of HCC epitopes. Four HCC epitopes MAGE-1(278-286aa), MAGE-3(271-279aa), AFP1 (158-166aa) or AFP2 (542-550aa) were fused to the 3' terminus of the truncated HBV core gene, respectively, or conjunctively. Not all recombinant plasmids led to expression of chimeric proteins in expression strain E. coli BL21 (DE3), but chimeric proteins which are expressed in inclusion bodies resulted in the formation of complete "mature" VLPs. E. coli-derived truncated HBc(1-144) chimeric protein self-assembled into VLPs that both morphologically and physically are similar to the wild-type ones and they still remained activity after purification and refolding from 6M urea solution. We also showed that they could be internalized and presented by DCs in vitro. Additionally, DCs pulsed with the chimeric HBc-VLPs could induce stronger CTL activity and greater IFN-gamma secretion by responding T cells compared with peptid-pulsed DCs. In the B16-pIR-HH tumor therapy model, the growth of established tumors was significantly inhibited by immunization using VLP-pulsed DCs, resulting in significantly higher survival rate of immunized animals. Thus, the results of the current study have demonstrated the principal possibility of using VLP on the basis of HBcAg for creation of a new type of HCC-specific immunogen.
Collapse
MESH Headings
- Animals
- Antibody Specificity/immunology
- Antigens, Neoplasm/chemistry
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Carcinoma, Hepatocellular/immunology
- Carcinoma, Hepatocellular/therapy
- Dendritic Cells/immunology
- Dendritic Cells/virology
- Epitopes/chemistry
- Epitopes/genetics
- Epitopes/immunology
- Escherichia coli/genetics
- Hepatitis B Antibodies/biosynthesis
- Hepatitis B Core Antigens/chemistry
- Hepatitis B Core Antigens/genetics
- Hepatitis B Core Antigens/immunology
- Hepatitis B Vaccines/biosynthesis
- Hepatitis B Vaccines/immunology
- Hepatitis B virus/chemistry
- Hepatitis B virus/immunology
- Humans
- Immunotherapy
- Interferon-gamma/metabolism
- Liver Neoplasms/immunology
- Liver Neoplasms/therapy
- Male
- Melanoma-Specific Antigens
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Neoplasm Proteins/chemistry
- Neoplasm Proteins/genetics
- Neoplasm Proteins/immunology
- Recombinant Fusion Proteins/chemistry
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- T-Lymphocytes, Cytotoxic/immunology
- Treatment Outcome
- Tumor Cells, Cultured
- Vaccines, Synthetic/chemistry
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- Yan Zhang
- Department of Molecular Biology, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang 050017, PR China
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Han X, Ye LB, Li BZ, Bo G, Cai WJ, Hong Z, She YL, Li Y, Kong LB, Wu ZH. Expression, purification and characterization of the Hepatitis B virus entire envelope large protein in Pichia pastoris. Protein Expr Purif 2006; 49:168-75. [PMID: 16829133 DOI: 10.1016/j.pep.2006.05.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2006] [Revised: 04/30/2006] [Accepted: 05/08/2006] [Indexed: 11/16/2022]
Abstract
The current HBsAg vaccine has performed a vital role in preventing the transmission of HBV during the past 20 years. However, a number of individuals still show no response or a low response to the vaccine. In the present study, the HBV envelope large protein gene was cloned into the eukaryotic expression vector pPIC9k and was subsequently expressed in the yeast Pichia pastoris. The HBV large protein (L protein) was produced and secreted into the medium, where some of the L protein formed particles. The soluble L protein and particles were purified by column chromatography and sucrose density gradient centrifugation. Western blot analysis demonstrated that the particle was composed of both HBV L and S protein. To compare the antigenicity of the L protein and HBsAg, rabbits were immunized with the soluble L protein and the commercially available HBV vaccine and the increasing level of antibodies was determined by ELISA. The results showed that the anti-HBsAg antibody, from rabbits injected with the L protein at a dose of 2 and 10microg, was detected on day 14, whereas rabbits vaccinated with 10 and 2microg HBsAg did not develop antibodies until day 21 and 28, respectively. The antibody level in groups inoculated with the L protein was approximately 50% higher than in the group injected with HBsAg using the same dose. Furthermore, 2microg L protein induced a significant and rapid anti-HBsAg antibody response than 10microg HBsAg. Therefore, we suggest that the L protein is an ideal candidate for a new generation HB vaccine to protect people from HBV infection.
Collapse
Affiliation(s)
- Xue Han
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, PR China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Shchelkunov SN, Salyaev RK, Rekoslavskaya NI, Ryzhova TS, Pozdnyakov SG, Sumtsova VM, Pakova NV, Mishutina UO, Kopytina TV, Hammond R. The Obtaining of Transgenic Tomato Plant Producing Chimerical Proteins TBI-HBsAg. DOKL BIOCHEM BIOPHYS 2004; 396:139-42. [PMID: 15378910 DOI: 10.1023/b:dobi.0000033512.53069.e8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S N Shchelkunov
- Vektor State Scientific Center of Virology and Biotechnology, p. Kol'tsovo, Novosibirsk oblast, 630559 Russia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Li YG, Chen M, Zhang DZ, Wang ZY, Zeng WQ, Shi XF, Guo Y, Guo SH, Ren H. [Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 2003; 11:206-8. [PMID: 12716515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To investigate the treatment effect of autologous HBsAg-loaded dendritic cells (DCs) on patients with chronic hepatitis B (CHB). METHODS Monocytes were isolated from fresh peripheral blood of 19 CHB patients by Ficoll-Hypaque density gradient centrifugating and cultured with plastic -adherence method. DCs were induced and proliferated from the monocytes with granulocyte-macrophage clony stimulating factor (GM-CSF) and interleukin-4 (IL-4) for seven days. After being incubated with HBsAg for two hours, DCs were injected to patients subcutaneously twice at the interval of two weeks. HBV DNA level, alanine aminotransferase (ALT) level, and HBV markers in the serum of patients were tested every two months. RESULTS 11 of the 19 (57.9%) patients responded to DC-treatment clinically. The rates of HBeAg clearance and HBeAg/anti-HBe seroconversion were 52.6% (10/19) and 26.3% (5/19) respectively, and the copies of HBV DNA decreased by 10(1.77 2.39) (t = 3.13, P < 0.01). Two patients who were treated in combination with lamivudine had complete clinical response. There was no difference in the trial effect between the DC treatment and the other two antiviral methods, and in the efficient rate between the patients whose ALT levels were high before treatment and those whose ALT levels were normal. CONCLUSION The autologous HBsAg-loaded DCs can effectively suppress HBV replication, reduce virus load in serum, eliminate HBeAg and promote HBeAg/ anti-HBe seroconversion. The patients whose ALT levels are high or normal can response clinically to DCs treatment. DCs in combination with lamivudine can eliminate virus more effectively.
Collapse
Affiliation(s)
- Yong-guo Li
- Liver Disease Center of Chongqing, Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Smith ML, Mason HS, Shuler ML. Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol Bioeng 2002; 80:812-22. [PMID: 12402327 DOI: 10.1002/bit.10444] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The production of edible vaccines in transgenic plants and plant cell culture may be improved through a better understanding of antigen processing and assembly. The hepatitis B surface antigen (HBsAg) was chosen for study because it undergoes substantial and complex post-translational modifications, which are necessary for its immunogenicity. This antigen was expressed in soybean (Glycine max L. Merr. cv Williams 82) and tobacco NT1 (Nicotiana tabacum L.) cell suspension cultures, and HBsAg production in batch culture was characterized. The plant-derived antigen consisted predominantly of disulfide cross-linked HBsAg protein (p24(s)) dimers, which were all membrane associated. Similar to yeast, the plant-expressed HBsAg was retained intracellularly. The maximal HBsAg titers were obtained with soybean suspension cultures (20-22 mg/L) with titers in tobacco cultures being approximately 10-fold lower. For soybean cells, electron microscopy and immunolocalization demonstrated that all the HBsAg was localized to the endoplasmic reticulum (ER) and provoked dilation and proliferation of the ER network. Sucrose gradient analysis of crude extracts showed that HBsAg had a complex size distribution uncharacteristic of the antigen's normal structure of uniform 22-nm virus-like particles. The extent of authentic epitope formation was assessed by comparing total p24(s) synthesized to that reactive by polyclonal and monoclonal immunoassays. Depending on culture age, between 40% and 100% of total p24(s) was polyclonal antibody reactive whereas between 6% and 37% was recognized by a commercial monoclonal antibody assay. Possible strategies to increase HBsAg production and improve post-translational processing are discussed.
Collapse
Affiliation(s)
- Mark L Smith
- Department of Chemical Engineering, Cornell University, Ithaca, New York 14853, USA.
| | | | | |
Collapse
|
17
|
Valdés R, Ibarra N, Ruibal I, Beldarraín A, Noa E, Herrera N, Alemán R, Padilla S, Garcia J, Pérez M, Morales R, Chong E, Reyes B, Quiñones Y, Agraz A, Herrera L. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses. J Biotechnol 2002; 96:251-8. [PMID: 12044553 PMCID: PMC7126170 DOI: 10.1016/s0168-1656(02)00047-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
The virus removal of protein A affinity chromatography, inactivation capacity, acid pH and a combination of high temperature with a chaotropic agent was determined in this work. The model viruses studied were sendaivirus, human immunodeficency virus (HIV-IIIb), human poliovirus type-II, human herpesvirus I and canine parvovirus. The protein A affinity chromatography showed a maximum reduction factor of 8 logs in the case of viruses larger than 120 nm size, while for small viruses (18-30 nm) the maximum reduction factor was about 5 logs. Non viral inactivation was observed during the monoclonal antibody elution step. Low pH treatment showed a maximum inactivation factor of 7.1 logs for enveloped viruses. However, a weak inactivation factor (3.4 logs) was obtained for DNA nonenveloped viruses. The combination of high temperature with 3 M KSCN showed a high inactivation factor for all of the viruses studied. The total clearance factor was 23.1, 15.1, 13.6, 20.0 and 16.0 logs for sendaivirus, HIV-IIIb, human poliovirus type-II, human herpesvirus I and canine parvovirus, respectively.
Collapse
Affiliation(s)
- R Valdés
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - Neysi Ibarra
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
- Corresponding author. Tel.: +53-7-271-6022; fax: +53-7-271-3208
| | - I Ruibal
- National Reference Center for AIDS, PO Box 23031, Havana, Cuba
| | - A Beldarraín
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - E Noa
- National Reference Center for AIDS, PO Box 23031, Havana, Cuba
| | - N Herrera
- National Reference Center for AIDS, PO Box 23031, Havana, Cuba
| | - R Alemán
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - S Padilla
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - J Garcia
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - M Pérez
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - R Morales
- National Center for Bioreagents, PO Box 6048, Havana, Cuba
| | - E Chong
- National Center for Bioreagents, PO Box 6048, Havana, Cuba
| | - B Reyes
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - Y Quiñones
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - A Agraz
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - L Herrera
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| |
Collapse
|
18
|
Abstract
The ability of the Pichia pastoris-based technology for large-scale production of recombinant hepatitis B virus surface antigen (HBsAg) and both reproducibly purify HBsAg and remove most of the relevant contaminants was ascertained by evaluating ten industrial production batches, five in 1993 and five in 1998. At an early stage, the clarification of mechanically disrupted yeast cells by acid precipitation renders HBsAg with a purity as low as 3.8 +/- 0.6%. However, by adsorption/desorption from diatomaceous earth matrix, the purity of HBsAg rapidly increases to 18.8 +/- 5%, which is suitable for chromatographic processing. This step also eliminates non-particulated forms of HBsAg, significantly lowers the amount of carbohydrates and lipids, and concentrates the HBsAg 4.8-fold. Finally, a sequential purification procedure that includes large-scale immunoaffinity, ion-exchange, and size-exclusion chromatographies further purifies the preparation, resulting in a product (HBsAg at a concentration of 1.3 +/- 0.2 g l-1) with a purity of 95% or more. Furthermore, each of the other contaminants measured reaches the following low levels per 20 micrograms HBsAg: host deoxyribonucleic acid (< 10 pg), carbohydrates (1.2 +/- 0.02 micrograms), lipids (14 +/- 0.28 micrograms), immunopurification-released immunoglobulin G (less than 100 ppm), and endotoxins (106.7 +/- 19.3 pg). These values are below those specified for recombinant DNA hepatitis B vaccines according to World Health Organization (WHO) guidelines.
Collapse
Affiliation(s)
- E Hardy
- Center for Genetic Engineering and Biotechnology, Havana, Cuba.
| | | | | | | | | | | |
Collapse
|
19
|
Kniskern PJ, Hagopian A, Burke P, Schultz LD, Montgomery DL, Hurni WM, Ip CY, Schulman CA, Maigetter RZ, Wampler DE. Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation. Vaccine 1994; 12:1021-5. [PMID: 7975842 DOI: 10.1016/0264-410x(94)90339-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The hepatitis B (HB) virus preS2 + 2 polypeptide (the M or middle envelope polypeptide) is N-glycosylated at the N4 residue of the preS2 domain when expressed in recombinant yeast. Hyperglycosylation at this amino acid residue (the addition of a large number of mannose residues to the core oligosaccharide), which occurs in common yeast strains, results in an HB vaccine with diminished immunogenicity. Hyperglycosylation can be prevented by expressing the preS2 + S polypeptide in mutant yeast strains (e.g. mnn9) which limit N-linked glycosylation to the addition of only core saccharide residues. An HB vaccine prepared from recombinant yeast expressing the non-hyperglycosylated preS2 + 2 polypeptide was of similar immunogenicity in mice to a licensed HB vaccine and was much more immunogenic in humans than the hyperglycosylated preS2 + 2 vaccine.
Collapse
Affiliation(s)
- P J Kniskern
- Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Schödel F, Kelly SM, Peterson DL, Milich DR, Curtiss R. Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect Immun 1994; 62:1669-76. [PMID: 8168928 PMCID: PMC186381 DOI: 10.1128/iai.62.5.1669-1676.1994] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Avirulent salmonellae expressing foreign genes are attractive for use as oral vaccine carriers. To facilitate the stable expression of heterologous genes without conferring antibiotic resistance, a deletion of the asdA1 gene was introduced into Salmonella typhimurium and S. typhi delta cya delta crp mutant vaccine strains. An asd-complementing plasmid expressing hybrid hepatitis B virus nucleocapsid-pre-S (HBcAg-pre-S) particles was constructed. These hybrid HBcAg-pre-S particle genes were stably expressed in S. typhimurium and S. typhi delta cya delta crp mutant vaccine strains in this balanced, lethal host-vector combination. A single oral immunization of BALB/c mice with a recombinant S. typhimurium delta cya delta crp mutant synthesizing hybrid HBcAg-pre-S elicited potentially virus-neutralizing anti-pre-S serum immunoglobulin G antibodies. In addition, serum immunoglobulin G recognizing S. typhimurium lipopolysaccharide was induced. Distribution in tissue after oral immunization was analyzed in one plasmid-strain combination. The recombinant S. typhimurium colonized the gut-associated lymphoid tissue and the spleen and persisted for over 4 weeks, retaining the HBcAg-pre-S expression plasmid. An isogenic virulence plasmid-cured S. typhimurium delta cya delta crp strain expressing the same HBcAg-pre-S gene had reduced immunogenicity for the carried antigen after oral immunization.
Collapse
Affiliation(s)
- F Schödel
- Max-Planck-Institut für Biochemie, Martinsried, Germany
| | | | | | | | | |
Collapse
|